Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Bladder Cancer

  Free Subscription


1 Actas Urol Esp (Engl Ed)
1 Biochem Genet
1 Biol Direct
5 BJU Int
1 BJUI Compass
1 BMC Urol
1 Bratisl Lek Listy
1 Cancer Immunol Immunother
6 Cancers (Basel)
1 Cell Genom
2 Clin Genitourin Cancer
1 Curr Opin Urol
1 Egypt J Immunol
3 Eur Urol
1 Eur Urol Oncol
1 Front Immunol
1 Georgian Med News
2 Int J Mol Sci
13 Int J Urol
1 iScience
1 J Cancer Res Clin Oncol
1 J Clin Med
1 J Clin Oncol
1 J Clin Tuberc Other Mycobact Dis
1 J Immunother Cancer
1 J Transl Med
2 JCO Precis Oncol
1 Med Biol Eng Comput
1 Mol Carcinog
1 Nat Rev Urol
1 NPJ Digit Med
5 Urol Oncol
1 Urology
1 World J Urol
1 Zhonghua Nan Ke Xue

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Actas Urol Esp (Engl Ed)

    Implementation of new treatments for BCG-unresponsive non-muscle-invasive bladder cancer. Considerations in Latin America.
    Actas Urol Esp (Engl Ed). 2024 Apr 12:S2173-5786(24)00058.

    Biochem Genet

  2. XIE T, Guo J, Wang W
    The Long Noncoding RNA Gall Bladder Cancer-Associated Suppressor of Pyruvate Carboxylase Inhibits the Proliferation, Migration, and Invasion of Colorectal Cancer Cells and Induces Their Apoptosis.
    Biochem Genet. 2024 Apr 12. doi: 10.1007/s10528-024-10786.
    PubMed         Abstract available

    Biol Direct

  3. SHEN D, Kang S
    Correction: Comprehensive analysis of mitochondria-related genes indicates that PPP2R2B is a novel biomarker and promotes the progression of bladder cancer via Wnt signaling pathway.
    Biol Direct. 2024;19:27.

    BJU Int

  4. LAUKHTINA E, Gontero P, Babjuk M, Moschini M, et al
    Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder cancer.
    BJU Int. 2024 Apr 16. doi: 10.1111/bju.16371.
    PubMed         Abstract available

  5. DITONNO F, Veccia A, Montanaro F, Pettenuzzo G, et al
    Trimodal therapy vs radical cystectomy in patients with muscle-invasive bladder cancer: a systematic review and meta-analysis of comparative studies.
    BJU Int. 2024 Apr 15. doi: 10.1111/bju.16366.
    PubMed         Abstract available

  6. LONGONI M, Scilipoti P, Re C, Rosiello G, et al
    Use of 18F-fluoro-2-deoxy-d-glucose (18F-FDG) PET/CT for lymph node assessment before radical cystectomy in bladder cancer patients.
    BJU Int. 2024 Apr 15. doi: 10.1111/bju.16363.
    PubMed         Abstract available

  7. VAN KESSEL CS, Palma CA, Solomon MJ, Leslie S, et al
    Comparison of urological outcomes and quality of life after pelvic exenteration: partial vs radical cystectomy.
    BJU Int. 2024;133 Suppl 4:53-63.
    PubMed         Abstract available

  8. BOTROS A, Rival PM, Page F, Davis ID, et al
    Quality of transurethral resection of bladder tumour documentation: implications for non-muscle-invasive bladder cancer risk stratification and management.
    BJU Int. 2024;133 Suppl 4:7-10.

    BJUI Compass

  9. AL-ZUBAIDI M, Ong K, Viswambaram P, Bangash H, et al
    Comparing fluorodeoxyglucose positron emission tomography with computed tomography in staging for nodal and distant metastasis in urothelial/bladder cancer.
    BJUI Compass. 2024;5:473-479.
    PubMed         Abstract available

    BMC Urol

  10. YANG Y, Li J, Yao W, Zou G, et al
    Diagnostic value of urine cyclic RNA-0071196 for bladder urothelial carcinoma.
    BMC Urol. 2024;24:88.
    PubMed         Abstract available

    Bratisl Lek Listy

  11. VARCHULOVA NOVAKOVA Z, Harsanyi S, Bevizova K, Kuniakova M, et al
    Expression of BCL2, TP53, FOXA1, and GATA3 in pTa bladder cancer recurrence.
    Bratisl Lek Listy. 2024;125:311-317.
    PubMed         Abstract available

    Cancer Immunol Immunother

  12. MASSARI F, Santoni M, Takeshita H, Okada Y, et al
    Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
    Cancer Immunol Immunother. 2024;73:106.
    PubMed         Abstract available

    Cancers (Basel)

  13. YOO YC, Kim NY, Shin S, Yang Y, et al
    Anti-Proliferative Effects of Lidocaine as an Autophagy Inducer in Bladder Cancer via Intravesical Instillation: In Vitro and Xenograft Mouse Model Experiments.
    Cancers (Basel). 2024;16:1267.
    PubMed         Abstract available

  14. AFONSO J, Barbosa-Matos C, Silvestre R, Pereira-Vieira J, et al
    Cisplatin-Resistant Urothelial Bladder Cancer Cells Undergo Metabolic Reprogramming beyond the Warburg Effect.
    Cancers (Basel). 2024;16:1418.
    PubMed         Abstract available

  15. JAROMIN M, Konecki T, Kutwin P
    Revolutionizing Treatment: Breakthrough Approaches for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2024;16:1366.
    PubMed         Abstract available

  16. MAAS M, Hilsendecker A, Pertoll A, Stuhler V, et al
    PD-L1 Expression in High-Risk Non-Muscle-Invasive Bladder Cancer Is Influenced by Intravesical Bacillus Calmette-Guerin (BCG) Therapy.
    Cancers (Basel). 2024;16:1356.
    PubMed         Abstract available

  17. PERRI D, Rocco B, Sighinolfi MC, Bove P, et al
    Open versus Robot-Assisted Radical Cystectomy for the Treatment of pT4a Bladder Cancer: Comparison of Perioperative Outcomes.
    Cancers (Basel). 2024;16:1329.
    PubMed         Abstract available

  18. LADI-SEYEDIAN SS, Ghoreifi A, Konety B, Pohar K, et al
    Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry.
    Cancers (Basel). 2024;16:1268.
    PubMed         Abstract available

    Cell Genom

  19. NAKAUMA-GONZALEZ JA, Rijnders M, Noordsij MTW, Martens JWM, et al
    Whole-genome mapping of APOBEC mutagenesis in metastatic urothelial carcinoma identifies driver hotspot mutations and a novel mutational signature.
    Cell Genom. 2024;4:100528.
    PubMed         Abstract available

    Clin Genitourin Cancer

  20. KLEMM J, Shariat SF, Laukhtina E, Rajwa P, et al
    Impact of Preoperative Plasma Potassium Levels on Oncological Outcomes, Major Complications, and 30-Day Mortality in Bladder Cancer Patients Undergoing Radical Cystectomy.
    Clin Genitourin Cancer. 2024 Mar 21:102079. doi: 10.1016/j.clgc.2024.102079.
    PubMed         Abstract available

  21. WANG A, Chen M, Li D, Shi J, et al
    Disitamab Vedotin Alone or in Combination With Immune Checkpoint Inhibitors in Bladder-Sparing Treatment of Muscle-Invasive Bladder Cancer: A Real-World Study.
    Clin Genitourin Cancer. 2024;22:102085.
    PubMed         Abstract available

    Curr Opin Urol

  22. ERTL I, Shariat SF, Berger W, Englinger B, et al
    Preclinical models for bladder cancer therapy research.
    Curr Opin Urol. 2024 Apr 17. doi: 10.1097/MOU.0000000000001182.
    PubMed         Abstract available

    Egypt J Immunol

  23. ABD ELHAMEED ZA, Tag El Din LM, Sherif T, Abdel Aal AM, et al
    Plasma metadherin mRNA expression in bladder cancer.
    Egypt J Immunol. 2024;31:28-43.
    PubMed         Abstract available

    Eur Urol

  24. ST-LAURENT MP, Black PC
    Re: FGFR Inhibition Augments Anti-PD-1 Efficacy in Murine FGFR3-mutant Bladder Cancer by Abrogating Immunosuppression.
    Eur Urol. 2024 Apr 12:S0302-2838(24)02259-0. doi: 10.1016/j.eururo.2024.

    Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion Versus Open Radical Surgery: All Is in the Eye of the Beholder.
    Eur Urol. 2024;85:431-432.

  26. MASTROIANNI R, Tuderti G, Ferriero M, Anceschi U, et al
    Robot-assisted Radical Cystectomy with Totally Intracorporeal Urinary Diversion Versus Open Radical Cystectomy: 3-Year Outcomes from a Randomised Controlled Trial.
    Eur Urol. 2024;85:422-430.
    PubMed         Abstract available

    Eur Urol Oncol

  27. RANA Z, Kamran SC, Shetty AC, Sutera P, et al
    Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712.
    Eur Urol Oncol. 2024 Apr 18:S2588-9311(24)00095.
    PubMed         Abstract available

    Front Immunol

  28. PEZESHKI A, Cheville JC, Florio AB, Leibovich BC, et al
    Evaluation of tumor response to immune checkpoint inhibitors by a 3D immunotumoroid model.
    Front Immunol. 2024;15:1356144.
    PubMed         Abstract available

    Georgian Med News

  29. VOVK V, Duda I, Vovk A
    Georgian Med News. 2024;:41-46.
    PubMed         Abstract available

    Int J Mol Sci

  30. PADULLES B, Carrasco R, Ingelmo-Torres M, Roldan FL, et al
    Prognostic Value of Liquid-Biopsy-Based Biomarkers in Upper Tract Urothelial Carcinoma.
    Int J Mol Sci. 2024;25:3695.
    PubMed         Abstract available

  31. BAEK SW, Leem SH
    A Multi-Gene Signature of Non-Muscle-Invasive Bladder Cancer Identifies Patients Who Respond to Immunotherapies Including Bacillus Calmette-Guerin and Immune Checkpoint Inhibitors.
    Int J Mol Sci. 2024;25:3800.
    PubMed         Abstract available

    Int J Urol

  32. URABE F
    Letter to the Editor Re: Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence upper tract urothelial carcinoma after radical nephroureterectomy.
    Int J Urol. 2024;31:420.

  33. HIYAMA Y
    Editorial comment to Lower bleeding volume contributes to decreasing surgical site infection in radical cystectomy: A propensity score-matched comparison of open versus robot-assisted radical cystectomy.
    Int J Urol. 2024;31:437.

  34. TAOKA R, Sugimoto M
    Editorial Comment on Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence for upper tract urothelial carcinoma after radical nephroureterectomy.
    Int J Urol. 2024;31:418-419.

  35. LUO HL
    Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence upper tract urothelial carcinoma after radical nephroureterectomy.
    Int J Urol. 2024;31:421.

  36. HAYAKAWA N, Kikuchi E
    Editorial comment to "The clinical impact of ureteroscopy for upper tract urothelial carcinoma: A multicenter study".
    Int J Urol. 2024;31:402-403.

  37. SAZUKA T
    Editorial Comment on "The clinical impact of ureteroscopy for upper tract urothelial carcinoma: A multicenter study".
    Int J Urol. 2024;31:401-402.

    Editorial comment from Dr Taguchi to Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study.
    Int J Urol. 2024;31:348.

  39. SOWANTHIP D, Zennami K, Bejrananda T, Nukaya T, et al
    Older versus younger patients in robot-assisted radical cystectomy with intracorporeal ileal conduit comparing safety and clinical outcomes.
    Int J Urol. 2024;31:370-378.
    PubMed         Abstract available

  40. KAMEI J, Endo K, Yamazaki M, Sugihara T, et al
    Lower bleeding volume contributes to decreasing surgical site infection in radical cystectomy: A propensity score-matched comparison of open versus robot-assisted radical cystectomy.
    Int J Urol. 2024;31:430-437.
    PubMed         Abstract available

  41. SASAHARA T, Yanagisawa T, Sugaya S, Hisakane A, et al
    Prognostic factors for overall survival in clinical node-positive patients with upper tract urothelial carcinoma.
    Int J Urol. 2024;31:386-393.
    PubMed         Abstract available

  42. YU TY, Wang HJ, Sung MT, Chuang YC, et al
    Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence for upper tract urothelial carcinoma after radical nephroureterectomy.
    Int J Urol. 2024;31:410-418.
    PubMed         Abstract available

  43. NAKANO J, Urabe F, Kiuchi Y, Takamizawa S, et al
    The clinical impact of ureteroscopy for upper tract urothelial carcinoma: A multicenter study.
    Int J Urol. 2024;31:394-401.
    PubMed         Abstract available

  44. URABE F, Ito K, Kimura T
    Letter to the Editor Re: Balancing diagnostic advancements with cardiovascular considerations in 5-aminolevulinic acid use for bladder tumors.
    Int J Urol. 2024;31:452.


  45. CHEN H, Wen J, Zhang W, Ma W, et al
    circKDM1A suppresses bladder cancer progression by sponging miR-889-3p/CPEB3 and stabilizing p53 mRNA.
    iScience. 2024;27:109624.
    PubMed         Abstract available

    J Cancer Res Clin Oncol

  46. LI J, Song Y, Peng Y, Lin J, et al
    The role of histological subtype and chemotherapy on prognosis of ureteral cancer.
    J Cancer Res Clin Oncol. 2024;150:192.
    PubMed         Abstract available

    J Clin Med

  47. PICHLER R, Stablein J, Mari A, Afferi L, et al
    Treating BCG-Induced Cystitis with Combined Chondroitin and Hyaluronic Acid Instillations in Bladder Cancer.
    J Clin Med. 2024;13:2031.
    PubMed         Abstract available

    J Clin Oncol

  48. SHENG X, Wang L, He Z, Shi Y, et al
    Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials.
    J Clin Oncol. 2024;42:1391-1402.
    PubMed         Abstract available

    J Clin Tuberc Other Mycobact Dis

  49. HARTERT M, Deppe C, Fink L, Kappes J, et al
    Chest wall tumor following intravesical BCG instillation for non-muscle invasive bladder cancer.
    J Clin Tuberc Other Mycobact Dis. 2024;35:100438.
    PubMed         Abstract available

    J Immunother Cancer

  50. MEGHANI K, Frydenlund N, Yu Y, Choy B, et al
    Spatial comparison of molecular features associated with resistance to pembrolizumab in BCG unresponsive bladder cancer.
    J Immunother Cancer. 2024;12:e008571.
    PubMed         Abstract available

    J Transl Med

  51. ZHENG K, Hai Y, Chen H, Zhang Y, et al
    Tumor immune dysfunction and exclusion subtypes in bladder cancer and pan-cancer: a novel molecular subtyping strategy and immunotherapeutic prediction model.
    J Transl Med. 2024;22:365.
    PubMed         Abstract available

    JCO Precis Oncol

  52. GONG J, Mita AC, Wei Z, Cheng HH, et al
    Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.
    JCO Precis Oncol. 2024;8:e2300407.
    PubMed         Abstract available

  53. GONG J, Mita AC, Wei Z, Cheng HH, et al
    Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1.
    JCO Precis Oncol. 2024;8:e2300406.
    PubMed         Abstract available

    Med Biol Eng Comput

  54. ZHAO X, Lai L, Li Y, Zhou X, et al
    A lightweight bladder tumor segmentation method based on attention mechanism.
    Med Biol Eng Comput. 2024;62:1519-1534.
    PubMed         Abstract available

    Mol Carcinog

  55. QING L, Li Q, Yang Y, Xu W, et al
    Hypoxia-mediated attenuation of EGLN2 inhibition of the NF-kappaB signaling pathway leads to the formation of a loop between HIF-1alpha and MUC1-C promoting chemoresistance in bladder cancer.
    Mol Carcinog. 2024 Apr 18. doi: 10.1002/mc.23725.
    PubMed         Abstract available

    Nat Rev Urol

    A CAF subpopulation promotes LVI in early-stage bladder cancer.
    Nat Rev Urol. 2024 Apr 15. doi: 10.1038/s41585-024-00881.

    NPJ Digit Med

  57. KWONG JCC, Wu J, Malik S, Khondker A, et al
    Predicting non-muscle invasive bladder cancer outcomes using artificial intelligence: a systematic review using APPRAISE-AI.
    NPJ Digit Med. 2024;7:98.
    PubMed         Abstract available

    Urol Oncol

  58. HERZBERG H, Ventura Y, Lifshitz K, Savin Z, et al
    Natural history and health care burden of non-curative treatment for muscle-invasive bladder cancer.
    Urol Oncol. 2024 Apr 18:S1078-1439(24)00365.
    PubMed         Abstract available

  59. FEBRIYANTO T, Muhammad F, Wijaya W, Oey O, et al
    Antibiotic use reduces the efficacy of immune checkpoint inhibitors in patients with urothelial carcinoma: A systematic review and meta-analysis.
    Urol Oncol. 2024;42:160.
    PubMed         Abstract available

  60. GREENBERG DR, Rhodes S, Bhambhvani HP, Gago LC, et al
    The association between frailty, hypogonadism, and postoperative outcomes among men undergoing radical cystectomy.
    Urol Oncol. 2024;42:161.
    PubMed         Abstract available

  61. MORRA S, Scheipner L, Baudo A, Jannello LMI, et al
    Regional differences in upper tract urothelial carcinoma patients across the United States.
    Urol Oncol. 2024;42:162.
    PubMed         Abstract available

  62. DALL CP, Mason JB, Goldman CC, Fabrizio G, et al
    Functional and oncologic outcomes of prostate capsule-sparing radical cystectomy: A systematic review and meta-analysis.
    Urol Oncol. 2024;42:121-132.
    PubMed         Abstract available


  63. SAHNI DS, Oberoi AS, Ramsaha S, Teahan S, et al
    Incidence of Ureteroenteric Anastomotic Strictures After Robotic vs Open Cystectomy in Adults.
    Urology. 2024;185:100-108.
    PubMed         Abstract available

    World J Urol

  64. WEBER A, Vignat J, Shah R, Morgan E, et al
    Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN estimates.
    World J Urol. 2024;42:237.
    PubMed         Abstract available

    Zhonghua Nan Ke Xue

  65. JIANG Q, Wei ZF, Xiong Y, Jiang B, et al
    [Identification of lncrnas associated with aniline toxicity in male bladder cancer and construction of tumor risk prediction models].
    Zhonghua Nan Ke Xue. 2023;29:790-798.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.